Table 5.
RER, immunochemistry, BRAF and KRAS mutations on resected lesions
| MSI | MMR protein loss of expression | BRAF V600-E mutation | KRAS mutation | |
|---|---|---|---|---|
| SSAs | 4.6% (1/22)a | 4.3% (1/23)a | 95% (19/20) | 5% (1/20)b |
| HPs | 0/8 | 0/7 | 50% (5/10)c | 0/10 |
| Conventional adenomas | 0/13 | 0/12 | 9.1% (1/11)d | 9.1% (1/11)e |
| Adenocarcinomas | 0/1 | 0/2 | Xf | Xf |
a
One proximal SSA in HGD < 10 mm with loss of expression of MLH1 and PMS2 (normal for MSH2 and MSH6) and methylation of promoter of the hMLH1 gene.
b
G12D and G12V mutations.
c
Four distal lesions.
d
One proximal TA in LGD.
e
G12A mutation in TVA in LGD.
f
Technical failure.
RER: replication error; MSI: microsatellite instability; MMR: mismatch repair; SSAs: sessile serrated adenomas; HPs: hyperplastic polyps; HGD: high-grade dysplasia; LGD: low-grade dysplasia; TA: tubular adenoma; TVA: tubulovillous adenoma.